Retinal Function in Patients with Adalimumab Treatment: Long-term Follow-up with Microperimetry. (17th February 2021)

• Record Type: Journal Article
• Authors: Szepessy, Zsuzsanna; Barboni, Mirella T. S.; Farkas, Alexandra; Nagy, Zoltán Zsolt; Németh, János
• Is Part Of: Ocular immunology and inflammation. Volume 29:Number 2(2021)
• Page Start: 370
• Page End: 375
• Publication Date: 2021-02-17
• Subjects: Adalimumab -- microperimetry -- spondyloarthropathy -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2019.1672198
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To examine the effects of a biological treatment (adalimumab) on visual function in patients with ankylosing spondylitis and in uveitic patients without macular edema during one-year treatment with adalimumab. Methods : Sixteen eyes of eight consecutive Caucasian patients treated with adalimumab were followed up using microperimetry (MAIA; CenterVue, Padova, Italy). Five patients had ankylosing spondylitis without uveitis, three patients had panuveitis without macular edema. Macular sensitivity and macular integrity were recorded. Results : During six-month follow-up, the average threshold did not change significantly ( p = .649). Macular integrity was stable ( p = .225). The macular sensitivity point analysis showed no significant effects (examination F(3, 56) = 0.494 and p = .688; point*examination F(108, 2016) = 0.688 and p = .994) during the follow-up. Conclusions : During one-year follow-up, adalimumab did not affect macular function, unlike the well-established maculopathy induced by hydroxychloroquine. Microperimetry may be considered when following-up macular function in patients undertaking adalimumab.